Oriola Corp Class B
0.76
EUR
-0.01
(-0.78%)
ISIN
FI0009014351
Return %
Stock
S&P 500
1Y
-31.65
14.20
3Y
-18.02
81.12
5Y
-56.57
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Quarterly Revenue
EUR
•
in mil. unless spec.Quarterly Earnings Per Share
EUR
•
in mil. unless spec.Quarterly Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Katarina Gabrielson
- Full Time Employees
- 801
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Orionintie 5 Espoo UU Finland 02200
- IPO Date
- Jul 3, 2006
- Website
- oriola.com
- Similar Companies
- Business
- Oriola Oyj is a Nordic health and wellbeing distributor and wholesaler that provides pharmaceutical distribution, wholesale of health products, and related advisory services to pharmaceutical companies, pharmacies, hospitals, retailers and other healthcare providers, with operations primarily in Finland and Sweden and a presence across the Nordic region; headquartered in Espoo, Finland, and founded in 1968 Oriola offers pharmaceutical logistics, dose-dispensing, research pharmacy services, regulatory affairs and quality, pharmacovigilance and medical information, market access and tenders, real-world evidence, and product and service support across consumer health, nutrition, vaccines and over-the-counter medicines Founded 1968; headquarters in Espoo, Finland; main operations in Finland and Sweden; serves pharmaceutical companies, pharmacies, hospitals, retailers and e-commerce platforms; subsidiaries include Kronans Apotek in Sweden and related distribution networks; strategic focus on strengthening Nordic logistics, expanding to new distribution centres, and modernising Finnish operations to提升 efficiency and meet evolving market requirements Main products and services: pharmaceutical distribution and wholesale of health and wellbeing products; vitamins, food supplements, sports nutrients, wound care, beauty and personal care items; vaccines and over-the-counter medicines; pharmaceutical logistics and dose dispensing; special licensed medicines import; research pharmacy services; advisory services including commercial data, clinical trials, regulatory affairs, quality, pharmacovigilance and medical information; market access and tender support; real world evidence and data services; sales support and medical translation; pharmacovigilance and medical information; patient support services; consumer health products and retail offerings in Finland and Sweden Latest major company changes: accelerates growth and modernises Finnish operations with a highly automated distribution centre in southern Finland, enhancing logistics capabilities and profitability; completes or advances significant changes negotiations for a new Finnish distribution centre and potential relocation of headquarters within Espoo while minimizing redundancies; ongoing strategic initiatives include expanding logistics capacity, relocating operations to a new site in Järvenpää, and elevated focus on Nordic market expansion and operational efficiency Industry and segments: healthcare distribution and services; consumer health and wellbeing; pharmaceutical logistics; dose distribution; regulatory and market access advisory; clinical and data services; supply chain optimization; Nordic pharmaceutical wholesale Target markets and customers: pharmaceutical manufacturers, pharmacies, hospitals, clinics, retailers, veterinarians, healthcare providers, and e-commerce platforms across Finland, Sweden and broader Nordic region Geographic footprint: Finland, Sweden (with scale in Kronans Apotek network in Sweden); Nordic-wide distribution and advisory services; expanding logistics footprint within Finland and cross-border capabilities in the region Subsidiaries and parent relationships: operates as an independent listed company within the Oriola group; ownership and corporate structure include strategic affiliates and subsidiaries supporting Nordic distribution and consumer health segments; part of the broader Nordic pharmaceutical supply chain ecosystem Recent branding or corporate actions: reinforces Nordic leadership in pharmaceutical distribution; invests in automated warehousing and logistics modernization; reorganisations and change negotiations linked to the planned Finnish distribution centre and headquarters relocation to Espoo relative to the Espoo site; no redundancies indicated in ongoing transitions